{"gene":"TNFRSF12A","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2003,"finding":"TWEAK binds Fn14 (TNFRSF12A) with physiological affinity; Fn14 is the cognate receptor for TWEAK and is a type I transmembrane protein and the smallest known TNFR superfamily member. Fn14 signals via recruitment of TNFR-associated factors (TRAFs).","method":"Receptor-ligand binding assays, cDNA cloning, transfection studies","journal":"Cytokine & growth factor reviews","confidence":"High","confidence_rationale":"Tier 2 / Strong — foundational receptor identification, replicated across multiple labs and review papers, consistent with the entire corpus","pmids":["12787562"],"is_preprint":false},{"year":2003,"finding":"TWEAK-induced osteoclast differentiation of RAW264.7 macrophages is not mediated by Fn14/TweakR (no Fn14 surface expression detected by flow cytometry; Fn14-neutralizing antibodies did not block the effect), suggesting a second TWEAK receptor (TweakR2) exists on these cells. In contrast, TWEAK binding to Fn14 in HT-29 cells activated NF-κB and JNK but only weakly activated MAPK, whereas TweakR2 activated NF-κB, MAPK and JNK.","method":"Flow cytometry, neutralizing antibodies, cell differentiation assays, signaling pathway analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single lab with multiple methods but the second receptor was never molecularly identified","pmids":["12794080"],"is_preprint":false},{"year":2003,"finding":"Recombinant murine TWEAK bound to murine Fn14-transfected cells and induced cell death. Anti-Fn14 monoclonal antibodies cross-reacting with murine Fn14 also induced cell death in Fn14-transfected cells. Peritoneal macrophages secreted soluble functional TWEAK that was cytotoxic to Fn14-expressing cells.","method":"cDNA transfection, monoclonal antibody generation, cytotoxicity assays, functional neutralization","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ligand-receptor functional assay in transfected cells, reciprocal antibody blocking, single lab","pmids":["12821115"],"is_preprint":false},{"year":2009,"finding":"Fn14 expression in cardiomyocytes is induced by FGF1, norepinephrine, angiotensin II, and mechanical stretch via the RhoA/ROCK kinase pathway; C3 exoenzyme (RhoA inhibitor), Y27632 (ROCK inhibitor), and siRNA knockdown of RhoA/ROCK each abolished Fn14 upregulation. TWEAK stimulation of Fn14-expressing cardiomyocytes promoted nuclear translocation of NF-κB and induced NF-κB-dependent genes (RANTES, MCP-1); siRNA knockdown of Fn14 inhibited TWEAK-induced NF-κB activation.","method":"siRNA knockdown, pharmacological inhibitors (C3 exoenzyme, Y27632), NF-κB nuclear translocation assay, neonatal rat cardiomyocyte culture","journal":"Basic research in cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (pharmacological + genetic inhibition), single lab","pmids":["19629561"],"is_preprint":false},{"year":2013,"finding":"Fn14 activation induces collagen expression in cardiac fibroblasts via RhoA-dependent nuclear translocation of myocardin-related transcription factor-A (MRTF-A/MAL). Fn14 activation also caused fibroblast proliferation and myofibroblast differentiation. Fn14 knockout mice showed substantially reduced RV fibrosis and dysfunction after pulmonary artery banding. Fn14 expression in cardiac fibroblasts is regulated by endothelin-1.","method":"Fn14 knockout mice, cell culture activation assays, RhoA/MRTF-A pathway analysis, histology","journal":"Basic research in cardiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout mouse model with defined phenotype plus mechanistic pathway (RhoA/MRTF-A/collagen) validated in vitro, multiple orthogonal methods","pmids":["23325387"],"is_preprint":false},{"year":2013,"finding":"Fn14 can self-associate into dimers independently of TWEAK binding; an 18-amino acid region within the Fn14 cytoplasmic domain mediates self-association. Dimerization occurs via an intermolecular disulfide bond at cysteine residue 122. A TWEAK-binding-deficient Fn14 deletion mutant retains the ability to activate the NF-κB pathway, demonstrating TWEAK-independent Fn14 signaling. Both endogenous and overexpressed Fn14 were detected in dimeric form under non-reducing SDS-PAGE.","method":"Deletion mutagenesis, non-reducing SDS-PAGE, NF-κB reporter assay in transfected cells, site-directed mutagenesis of Cys122","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis combined with biochemical dimerization assay and functional NF-κB readout, single lab with multiple orthogonal methods","pmids":["23750247"],"is_preprint":false},{"year":2013,"finding":"Anti-Fn14 monoclonal antibodies (PDL192, P4A8) selectively activate the alternative (non-canonical) NF-κB pathway but do not activate classical NF-κB, IL-8 production, or cell death. Oligomerization of anti-Fn14 antibodies (via protein G or FcγR binding) converts them into full agonists mimicking membrane TWEAK, activating both classical and alternative NF-κB pathways. Soluble TWEAK predominantly triggers the alternative NF-κB pathway, while membrane-bound TWEAK triggers all Fn14-associated pathways. This indicates the alternative NF-κB pathway responds to Fn14 dimerization alone.","method":"NF-κB reporter assays, IL-8 ELISA, cell death assays, antibody oligomerization with protein G, FcγR-mediated cross-linking","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple functional assays with defined mechanistic controls dissecting canonical vs. non-canonical NF-κB; antibody oligomerization experiments functionally discriminate signaling thresholds; single lab with multiple orthogonal methods","pmids":["23532848"],"is_preprint":false},{"year":2014,"finding":"FGF receptor-1 (FGFR-1) physically interacts with Fn14 in cardiomyocytes, as shown by co-immunoprecipitation and proximity ligation assay. This interaction is enhanced by their respective ligands FGF1 and TWEAK. FGF1-induced cardiomyocyte cell cycle reentry is blocked by Fn14 inhibition, and TWEAK-induced cell cycle activation is blocked by FGFR-1 signaling inhibition. Co-stimulation with FGF1 and TWEAK synergistically promotes cell cycle reentry via PI3K/Akt signaling.","method":"Co-immunoprecipitation, proximity ligation assay, cell cycle assays with pharmacological and genetic inhibition, PI3K/Akt pathway analysis","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — physical interaction confirmed by two independent methods (Co-IP and PLA) plus functional epistasis experiments, single lab","pmids":["24571920"],"is_preprint":false},{"year":2014,"finding":"Large-magnitude (12%) cyclic stretch induces Ca2+ influx and reactive oxygen species generation in osteoblasts, activating ASK1-JNK pathways, which transiently upregulate Fn14 gene expression. Cells with elevated Fn14 become sensitive to TWEAK-induced apoptosis. Small-magnitude (1%) stretch activates ERK and osteogenic gene expression, which is suppressed by JNK activated at high stretch.","method":"Cyclic stretch application, calcium imaging, ROS assays, gene expression analysis, JNK/p38 pathway inhibition, primary osteoblast validation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined mechanistic pathway (stretch→Ca2+→ROS→ASK1→JNK→Fn14 upregulation→TWEAK sensitivity) with multiple methods, single lab","pmids":["24446436"],"is_preprint":false},{"year":2014,"finding":"Fn14 depletion inhibits bone metastasis in prostate cancer experimental models; functional reconstitution of Fn14 with constitutively active IKKβ rescues this phenotype, placing Fn14 upstream of IKKβ-dependent NF-κB signaling in bone metastasis. Androgen receptor (AR) binding to the Fn14 enhancer decreases Fn14 expression, establishing AR as a transcriptional repressor of Fn14.","method":"Fn14 siRNA depletion, IKKβ reconstitution, chromatin immunoprecipitation (AR binding to Fn14 enhancer), in vivo bone metastasis models","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (IKKβ reconstitution) and ChIP for upstream regulation, single lab with multiple orthogonal methods","pmids":["24970477"],"is_preprint":false},{"year":2014,"finding":"Fn14 knockout in mice with RNA toxicity (myotonic dystrophy model) results in reduced muscle pathology and improved function. Anti-TWEAK antibody treatment similarly improved muscle histopathology and function. Fn14 induction in skeletal muscle correlates with NF-κB pathway activation in this disease context.","method":"Fn14 knockout mice, anti-TWEAK antibody treatment, muscle histopathology, functional assays, NF-κB pathway analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout and pharmacological antibody blocking converge on the same phenotypic rescue in vivo, demonstrating causal role of Fn14 in disease muscle pathology","pmids":["25504044"],"is_preprint":false},{"year":2015,"finding":"Fn14 expression in tumor cells (rather than host cells) is required for cancer-induced cachexia; tumors in Fn14-deficient or TWEAK-deficient hosts still cause cachexia comparable to wild-type mice, while anti-Fn14 antibodies targeting tumor Fn14 prevented tumor-induced inflammation and loss of fat and muscle mass, extending lifespan.","method":"Fn14-knockout and TWEAK-knockout mouse hosts with tumor transplantation, anti-Fn14 antibody treatment, body composition analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic host knockout demonstrates tumor-cell-autonomous Fn14 requirement; antibody intervention confirms functional necessity; multiple orthogonal approaches in single high-impact study","pmids":["26359988"],"is_preprint":false},{"year":2017,"finding":"TWEAK/Fn14 activation in hepatic stellate cells (LX-2 cells) promotes pro-inflammatory cytokine secretion (IL-8, IL-6, RANTES, MCP-1) via activation of NF-κB and STAT3 pathways. NF-κB and STAT3 interact with each other in this context, synergistically amplifying cytokine secretion. Fn14 siRNA knockdown inhibited these effects.","method":"ELISA, RT-PCR, Western blotting of pathway components, siRNA knockdown, co-immunoprecipitation of NF-κB/STAT3 interaction","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with multiple pathway readouts plus Co-IP of NF-κB/STAT3 interaction, single lab","pmids":["28411440"],"is_preprint":false},{"year":2018,"finding":"TRAF3IP2 (TRAF3 Interacting Protein 2) mediates TWEAK/Fn14-induced pro-fibrotic responses in cardiac fibroblasts. TWEAK upregulates TRAF3IP2 expression and promotes its nuclear translocation. Silencing TRAF3IP2 inhibited TWEAK-induced p38 MAPK, NF-κB and AP-1 activation, inflammatory cytokine expression, MMP/TIMP1 activation, collagen secretion, and fibroblast proliferation/migration. TRAF3IP2 knockout mice were protected from TWEAK-induced cardiac fibrosis and dysfunction in vivo.","method":"siRNA knockdown, TRAF3IP2 knockout mice, TWEAK infusion model, Western blotting, cardiac function assessment","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout in vivo combined with siRNA epistasis in vitro with multiple mechanistic readouts; TRAF3IP2 placed as causal downstream mediator of Fn14 signaling","pmids":["29981796"],"is_preprint":false},{"year":2018,"finding":"Visual experience induces Fn14 expression in excitatory thalamocortical neurons of the dorsal lateral geniculate nucleus. Fn14 knockout mice show deficits specifically in experience-dependent (not spontaneous activity-dependent) retinogeniculate refinement, with functionally weaker and structurally smaller retinogeniculate inputs, establishing Fn14 as a molecular link between sensory-driven gene expression and synaptic refinement.","method":"Single-nucleus RNA sequencing, Fn14 knockout mice, electrophysiology, structural synapse analysis","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout mouse with electrophysiological and structural readouts plus single-nucleus transcriptomics identifying cell-type-specific expression; multiple orthogonal methods in single rigorous study","pmids":["30033152"],"is_preprint":false},{"year":2018,"finding":"TWEAK/Fn14 activation in atrial myocytes mediates hypertrophy partly through the JAK2/STAT3 signaling pathway; siRNA inhibition of JAK2 or STAT3 attenuated TWEAK-induced HL-1 atrial myocyte hypertrophy. Fn14 knockdown counteracted TWEAK-induced increases in ANP and Troponin T.","method":"siRNA knockdown of Fn14, JAK2, and STAT3; measurement of hypertrophy markers (ANP, Troponin T, cell size)","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA pathway epistasis with multiple hypertrophy markers, single lab","pmids":["29971943"],"is_preprint":false},{"year":2018,"finding":"TWEAK/Fn14 activation in keratinocytes promotes BP180 loss and reduced cell adhesion via activation of ERK and NF-κB pathways and downstream ADAM17. siRNA silencing of ADAM17 blocked TWEAK-induced BP180 loss, placing ADAM17 downstream of Fn14 signaling in this context. Fn14 siRNA preserved BP180 expression and protected cells from losing adherence.","method":"siRNA knockdown of Fn14 and ADAM17, Western blotting of ERK and NF-κB, cell adhesion assays","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA epistasis identifying ADAM17 as downstream effector, multiple pathway readouts, single lab","pmids":["28351660"],"is_preprint":false},{"year":2019,"finding":"Fn14 expression is increased in dorsal root ganglion (DRG) neurons following peripheral nerve injury. Blocking Fn14 increase attenuated SNL-induced pain hypersensitivity. Conversely, mimicking Fn14 increase produced pain hypersensitivity in the absence of injury. Mechanistically, increased Fn14 activated the NF-κB pathway through promoting p65 nuclear translocation in injured DRG neurons.","method":"Spinal nerve ligation model, Fn14 siRNA knockdown, Fn14 overexpression, NF-κB p65 nuclear translocation assay, behavioral pain testing","journal":"Molecular neurobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with mechanistic NF-κB readout in primary neurons, single lab","pmids":["30976982"],"is_preprint":false},{"year":2021,"finding":"ThPOK (ZBTB7B) functions as a transcriptional repressor of TNFRSF12A (Fn14) by binding directly to the TNFRSF12A promoter. ThPOK knockdown elevated TNFRSF12A levels in gastric cancer cells. TNFRSF12A activates the NF-κB pathway and regulates T cell proliferation in a gastric cancer co-culture context.","method":"ChIP (ThPOK binding to TNFRSF12A promoter), siRNA knockdown, luciferase reporter, NF-κB pathway analysis, T cell co-culture assays","journal":"Cytokine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirms direct promoter binding; functional readouts with siRNA, single lab","pmids":["34353698"],"is_preprint":false},{"year":2023,"finding":"Bile acids induce TNFRSF12A expression by enhancing c-JUN transcription factor binding to the TNFRSF12A promoter. TNFRSF12A then initiates hepatocyte pyroptosis via NFκB/Caspase-1/GSDMD signaling. Genetic ablation of Tnfrsf12a in cholestatic mice significantly reduced hepatocyte pyroptosis and cholestatic liver injury. TWEAK from infiltrated macrophages enhanced TNFRSF12A-induced hepatocyte pyroptosis.","method":"Tnfrsf12a knockout mice (BDL and DDC models), ChIP assay (c-JUN binding), Western blotting (Caspase-1, GSDMD cleavage), primary hepatocyte culture, human liver tissue samples","journal":"Cell death discovery","confidence":"High","confidence_rationale":"Tier 1 / Moderate — genetic knockout with defined pyroptosis phenotype plus ChIP for upstream transcriptional regulation and biochemical pathway characterization, multiple orthogonal methods, single lab","pmids":["36690641"],"is_preprint":false},{"year":2022,"finding":"TWEAK/Tnfrsf12a axis activates RIPK1-dependent apoptosis (not necroptosis or pyroptosis) in hepatocytes during acute liver failure. Inhibition of the TWEAK/Tnfrsf12a axis markedly attenuated acute liver failure in TAA and APAP models. This distinguishes Tnfrsf12a-induced cell death mechanism in hepatocytes as RIPK1-dependent apoptosis.","method":"Tnfrsf12a inhibition, TAA and APAP liver failure mouse models, RIPK1 pathway analysis, discrimination from necroptosis/pyroptosis by specific pathway inhibitors, human liver biopsy validation","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined mechanistic cell death pathway with pharmacological inhibition in two independent mouse models, single lab","pmids":["35853848"],"is_preprint":false},{"year":2023,"finding":"Fn14 is expressed by Prominin-1 (Prom1)-expressing hepatic progenitor cells (HPCs). TWEAK/Fn14 signaling promotes HPC proliferation and profibrogenic ductular reactions; Fn14 antagonism decreased ductular reactions, biliary fibrosis, periportal fibroblast activation, and noncanonical NF-κB signaling in a mouse model of biliary atresia. Recombinant TWEAK accelerated organoid growth, blocked by Fn14 antagonist.","method":"Fn14 antagonist treatment in RRV biliary atresia model, HPC organoid assays, CRISPR-based analysis, NF-κB signaling pathway analysis, RNA sequencing","journal":"Hepatology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological Fn14 blockade in vivo plus organoid gain/loss-of-function assays with mechanistic pathway readout, single lab","pmids":["36626628"],"is_preprint":false},{"year":2023,"finding":"Fn14 promotes myoblast fusion during skeletal muscle regeneration. Conditional deletion of Fn14 in myoblasts (but not differentiated myofibers) impairs muscle regeneration. Fn14 overexpression in myoblasts increases myotube diameter. Fn14 deletion reduces canonical Wnt and calcium signaling components; forced Wnt activation rescues fusion defects in Fn14-deficient myoblasts, placing Fn14 upstream of Wnt signaling in myoblast fusion.","method":"Conditional Fn14 knockout in myoblasts, global Fn14 knockout mice, Fn14 overexpression, muscle injury/regeneration model, Wnt pathway rescue experiments, in vitro differentiation assays","journal":"Life science alliance","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional knockout distinguishes myoblast-autonomous function; Wnt pathway rescue provides epistatic placement; multiple orthogonal in vivo and in vitro methods","pmids":["37813488"],"is_preprint":false},{"year":2024,"finding":"Constitutive Fn14 signaling in TNBC rewires the transcriptomic and epigenomic landscape, activating TNBC-specific super-enhancers (SEs) via chromatin looping to drive transcription of cancer dependency genes. One SE-driven target is NAMPT, whose upregulation promotes NAD+/ATP metabolic reprogramming critical for filopodia formation and metastasis.","method":"Fn14 overexpression/knockdown, H3K27ac ChIP-seq (super-enhancer mapping), Hi-C chromatin looping, NAMPT inhibition, in vivo xenograft metastasis models, metabolic profiling","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — chromatin-level mechanistic dissection (ChIP-seq + Hi-C) with functional NAMPT-metabolic-metastasis axis validated in vivo, multiple orthogonal methods in single study","pmids":["38965263"],"is_preprint":false},{"year":2025,"finding":"TWEAK-Fn14 signaling in lung fibroblasts/myofibroblasts inhibits fibroblast activation and ECM synthesis, and induces chemokine expression to recruit monocytes/macrophages. Fn14 deficiency increases ECM production, impairs macrophage infiltration/differentiation, and exacerbates bleomycin-induced lung fibrosis. Fn14 deficiency specifically diminishes an injury-induced SiglecF- CD11b- MHCIIlo intermediate macrophage subpopulation that promotes AT2 cell proliferation in organoids, indicating a protective role for Fn14 signaling in pulmonary fibrosis.","method":"Fn14 knockout mice, bleomycin lung fibrosis model, macrophage flow cytometry, organoid co-culture, ECM quantification","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with mechanistic dissection of macrophage subtype and organoid functional readout, multiple orthogonal methods identifying a protective (not pathological) role of Fn14 in pulmonary fibrosis","pmids":["39827460"],"is_preprint":false},{"year":2011,"finding":"Soluble TWEAK induced surface expression of RANKL by human immature STRO-1+ osteoblasts, establishing a mechanism by which TWEAK/Fn14 signaling could promote bone erosion indirectly through osteoblast-mediated osteoclastogenesis. Direct stimulation of PBMC by sTWEAK did not stimulate osteoclast formation.","method":"Flow cytometry for RANKL surface expression on osteoblasts, osteoclastogenesis assays from PBMC","journal":"Arthritis research & therapy","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single functional assay demonstrating TWEAK-induced RANKL upregulation on osteoblasts; negative result for direct osteoclastogenesis informs the mechanism","pmids":["21435232"],"is_preprint":false},{"year":2013,"finding":"TWEAK increased HMGB1 mRNA expression and protein secretion in monocytes via Fn14/NF-κB and PI3K signaling; blocking anti-Fn14 antibody or NF-κB/PI3K inhibitors reversed this effect. TWEAK-mediated HMGB1 increase was only observed in M1 macrophages, not M2 macrophages. TWEAK-induced MCP-1 secretion was blocked by HMGB1 siRNA, placing HMGB1 downstream of Fn14 in MCP-1 production.","method":"Anti-Fn14 blocking antibody, NF-κB and PI3K inhibitors, HMGB1 siRNA, ELISA, in vivo TWEAK injection and TWEAK-blocking antibodies in ApoE-/- mice","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and siRNA epistasis with in vivo validation, single lab","pmids":["23288170"],"is_preprint":false},{"year":2010,"finding":"TWEAK acting on Fn14 induces apoptosis in endometrial cancer cells via caspase pathways, decreasing cell viability.","method":"Caspase activation assays, cell viability assays with recombinant TWEAK treatment","journal":"Cancer letters","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single method (caspase assay), single lab, limited mechanistic detail in abstract","pmids":["20189297"],"is_preprint":false},{"year":2014,"finding":"TWEAK-Fn14 signaling induces NF-κB-dependent upregulation of Mcl-1 in NSCLC cells, conferring Mcl-1-dependent resistance to chemotherapy and radiotherapy. Depletion of Mcl-1 (siRNA or pharmacological inhibitor EU-5148) sensitized TWEAK-treated NSCLC cells to cisplatin and radiation. Inhibition of Bcl-2/Bcl-xL had minimal effect on TWEAK-induced survival.","method":"siRNA knockdown of Mcl-1 and Fn14, pharmacological Mcl-1 inhibitor, cisplatin/radiation survival assays, NF-κB pathway analysis","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological epistasis placing Mcl-1 downstream of Fn14/NF-κB for chemo/radioresistance, single lab with multiple methods","pmids":["24469836"],"is_preprint":false},{"year":2023,"finding":"TWEAK-Fn14-RelB (alternative NF-κB) signaling axis promotes cancer stem-like cell features in ovarian cancer cells after chemotherapy, including spheroid formation, asymmetric division, SOX2 expression, and EMT gene expression (VIM, ZEB1). A small-molecule Fn14 inhibitor blocking this cascade prolongs survival following carboplatin in a mouse ovarian cancer model.","method":"Fn14 small-molecule inhibitor, spheroid formation assay, asymmetric division assay, gene expression analysis, in vivo mouse ovarian cancer model","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological Fn14 blockade with multiple stem cell phenotype readouts plus in vivo survival, single lab","pmids":["36214671"],"is_preprint":false},{"year":2012,"finding":"NFAT1 transcription factor increases TWEAKR (Fn14) mRNA expression in breast cancer cells. The NFAT1-LCN2 axis regulates TWEAKR expression at the RNA level. TWEAKR mediates an anti-invasive effect in breast cancer cells.","method":"NFAT1 overexpression/knockdown, LCN2 expression analysis, TWEAKR expression measurement, invasion assays","journal":"Journal of cell science","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, limited mechanistic detail on how NFAT1 regulates TWEAKR in abstract","pmids":["22767506"],"is_preprint":false},{"year":2014,"finding":"HGF/MET receptor activation significantly upregulates Fn14 mRNA and protein expression in NSCLC cells. Fn14 depletion is sufficient to inhibit MET-driven NSCLC tumor cell migration and invasion in vitro, placing Fn14 downstream of MET signaling for invasion.","method":"HGF treatment, Fn14 siRNA knockdown, migration/invasion assays, protein expression analysis","journal":"Clinical & experimental metastasis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA epistasis placing Fn14 downstream of MET for invasion with multiple complementary assays, single lab","pmids":["24710956"],"is_preprint":false}],"current_model":"TNFRSF12A (Fn14) is a highly inducible type I transmembrane receptor—the smallest TNFR superfamily member—that is activated by its cognate TNF-family ligand TWEAK; upon TWEAK binding, Fn14 recruits TRAFs to activate both canonical and non-canonical NF-κB pathways (with soluble TWEAK preferentially driving alternative NF-κB and membrane TWEAK driving both), as well as JNK, MAPK, PI3K/Akt, RhoA/MRTF-A, JAK2/STAT3, and RIPK1-dependent apoptosis cascades depending on cell context; Fn14 can also self-associate via a cytoplasmic disulfide bond at Cys122 to trigger TWEAK-independent NF-κB signaling when highly overexpressed; its expression is transcriptionally regulated by growth factors (FGF1), cytokines, mechanical stress (via RhoA/ROCK), hypoxia (via HIF-1α), androgen receptor (repressor), c-JUN (bile acid-induced), and ThPOK (repressor), while physically interacting with FGFR-1 to synergize in PI3K/Akt-driven cardiomyocyte cell cycle reentry; functionally, Fn14 is required for experience-dependent retinogeniculate synaptic refinement, myoblast fusion via Wnt/calcium signaling, burn wound healing, cardiac fibrosis via RhoA/MRTF-A/collagen, cancer cachexia (tumor cell-autonomous), and TNBC super-enhancer-driven NAMPT metabolic reprogramming for metastasis, while playing a protective anti-fibrotic role in the lung by restraining fibroblast activation and supporting pro-regenerative macrophage recruitment."},"narrative":{"mechanistic_narrative":"TNFRSF12A (Fn14) is the cognate receptor for the TNF-family ligand TWEAK and the smallest TNFR superfamily member, signaling through recruitment of TRAFs to drive predominantly NF-κB-based transcriptional responses in a highly cell-context-dependent manner [PMID:12787562]. Ligand engagement activates canonical and non-canonical NF-κB, with soluble TWEAK and receptor dimerization preferentially triggering the alternative pathway while membrane-bound TWEAK (or oligomerized agonist antibodies) engages the full repertoire of Fn14 signaling [PMID:23532848]; Fn14 can additionally self-associate via an intermolecular disulfide bond at Cys122 to activate NF-κB independently of TWEAK [PMID:23750247]. Downstream, Fn14 couples to fibrogenic and inflammatory programs through RhoA-dependent MRTF-A nuclear translocation and collagen induction [PMID:23325387], the TRAF3IP2 adaptor driving p38/NF-κB/AP-1 activation [PMID:29981796], and JAK2/STAT3 signaling [PMID:29971943], and it physically interacts with FGFR-1 to synergize in PI3K/Akt-driven cardiomyocyte cell cycle reentry [PMID:24571920]. Fn14 expression is itself a highly inducible node, upregulated by mechanical stress via RhoA/ROCK [PMID:19629561], growth factor and cytokine cues [PMID:19629561, PMID:24710956], and bile acid-driven c-JUN binding [PMID:36690641], and repressed by androgen receptor [PMID:24970477] and ThPOK at the promoter [PMID:34353698]. Physiologically and pathologically, Fn14 mediates experience-dependent retinogeniculate synaptic refinement [PMID:30033152], myoblast fusion via Wnt/calcium signaling [PMID:37813488], cardiac and biliary fibrosis [PMID:23325387, PMID:36626628], hepatocyte cell death (RIPK1-dependent apoptosis and NF-κB/Caspase-1/GSDMD pyroptosis) [PMID:36690641, PMID:35853848], tumor-cell-autonomous cancer cachexia [PMID:26359988], and super-enhancer-driven NAMPT metabolic reprogramming for breast cancer metastasis [PMID:38965263], while conversely restraining fibroblast activation and supporting pro-regenerative macrophage recruitment in the lung [PMID:39827460].","teleology":[{"year":2003,"claim":"Established the receptor identity of Fn14, answering what receptor transduces TWEAK signals and how it couples to downstream effectors.","evidence":"Receptor-ligand binding assays and transfection studies identifying Fn14 as the cognate TWEAK receptor signaling via TRAFs","pmids":["12787562"],"confidence":"High","gaps":["Did not define which TRAF members are recruited or the structural basis of recruitment","Did not resolve whether a second TWEAK receptor exists"]},{"year":2003,"claim":"Showed Fn14 engagement can produce divergent outputs (NF-κB/JNK vs. weak MAPK) and that some TWEAK effects are Fn14-independent, raising the possibility of a second receptor.","evidence":"Flow cytometry, neutralizing antibodies, and signaling pathway analysis in HT-29 and RAW264.7 cells; cytotoxicity assays in Fn14-transfected cells","pmids":["12794080","12821115"],"confidence":"Medium","gaps":["The proposed second TWEAK receptor (TweakR2) was never molecularly identified","Context-dependence of NF-κB vs. MAPK output not mechanistically resolved"]},{"year":2009,"claim":"Defined Fn14 as a mechanically and humorally inducible receptor, answering how its expression is controlled upstream of TWEAK responsiveness.","evidence":"siRNA and pharmacological RhoA/ROCK inhibition in neonatal rat cardiomyocytes with NF-κB readouts","pmids":["19629561"],"confidence":"Medium","gaps":["Did not identify the transcription factors executing RhoA/ROCK-dependent Fn14 induction","Restricted to cardiomyocyte context"]},{"year":2013,"claim":"Resolved how Fn14 drives fibrosis by linking it to a RhoA/MRTF-A/collagen transcriptional axis and demonstrating a causal role in cardiac remodeling.","evidence":"Fn14 knockout mice with pulmonary artery banding plus in vitro fibroblast activation and MRTF-A pathway analysis","pmids":["23325387"],"confidence":"High","gaps":["Did not define how Fn14 mechanistically activates RhoA","Cross-talk with NF-κB fibrotic outputs not delineated"]},{"year":2013,"claim":"Demonstrated TWEAK-independent signaling, answering whether Fn14 oligomerization alone is sufficient for activity and identifying Cys122 disulfide-mediated dimerization as the mechanism.","evidence":"Deletion and site-directed mutagenesis (Cys122), non-reducing SDS-PAGE, and NF-κB reporter assays","pmids":["23750247"],"confidence":"High","gaps":["Physiological relevance of self-association at endogenous expression levels not established","Did not test which signaling branches require dimerization vs. ligand"]},{"year":2013,"claim":"Dissected signaling thresholds, showing dimerization triggers alternative NF-κB while higher-order clustering (membrane TWEAK or oligomerized antibody) engages all pathways.","evidence":"NF-κB reporters, IL-8 ELISA, cell death assays, and antibody oligomerization via protein G/FcγR cross-linking","pmids":["23532848"],"confidence":"High","gaps":["Structural basis distinguishing dimer vs. higher-order signaling not resolved","TRAF-level mechanism of canonical vs. non-canonical selection not defined"]},{"year":2014,"claim":"Identified a direct Fn14–FGFR-1 physical interaction, answering how Fn14 can promote cardiomyocyte proliferation via PI3K/Akt cross-talk with growth factor receptors.","evidence":"Co-immunoprecipitation, proximity ligation assay, and cell cycle epistasis with PI3K/Akt analysis","pmids":["24571920"],"confidence":"High","gaps":["Structural interface of the Fn14–FGFR-1 complex unknown","Generality beyond cardiomyocytes not tested"]},{"year":2014,"claim":"Mapped multiple upstream regulators and disease contexts, establishing Fn14 induction by mechanical stretch, MET, and NFAT1, repression by AR, and roles in bone metastasis and muscle disease.","evidence":"Cyclic stretch with ASK1-JNK analysis (osteoblasts), HGF/MET and NFAT1 manipulation in cancer, ChIP and IKKβ reconstitution in bone metastasis, and knockout/anti-TWEAK rescue in a myotonic dystrophy model","pmids":["24446436","24710956","22767506","24970477","25504044"],"confidence":"High","gaps":["Context-specific reasons Fn14 is anti-invasive in some settings and pro-metastatic in others unresolved","How distinct transcription factors converge on the Fn14 locus not integrated"]},{"year":2015,"claim":"Localized the cachexia-driving Fn14 to tumor cells rather than host tissue, answering the cell-autonomy of Fn14 in cancer-induced wasting.","evidence":"Tumor transplantation into Fn14- and TWEAK-knockout hosts plus anti-Fn14 antibody intervention with body composition analysis","pmids":["26359988"],"confidence":"High","gaps":["The tumor-derived factors downstream of Fn14 that drive wasting not fully defined","Whether host TWEAK or autocrine ligand engages tumor Fn14 unresolved"]},{"year":2017,"claim":"Extended Fn14 inflammatory signaling to hepatic stellate cells, showing NF-κB/STAT3 cooperation amplifies cytokine output.","evidence":"siRNA knockdown, pathway Western blotting, and Co-IP of NF-κB/STAT3 in LX-2 cells","pmids":["28411440"],"confidence":"Medium","gaps":["Direct physical NF-κB/STAT3 interaction not validated reciprocally in vivo","In vivo relevance to liver fibrosis not shown in this study"]},{"year":2018,"claim":"Identified discrete downstream effectors (TRAF3IP2, JAK2/STAT3, ADAM17) and established a physiological CNS role, broadening the mechanistic and functional repertoire of Fn14.","evidence":"TRAF3IP2 knockout and siNA epistasis in cardiac fibroblasts, JAK2/STAT3 siRNA in atrial myocytes, ADAM17 siRNA in keratinocytes, and single-nucleus RNA-seq with knockout electrophysiology in dLGN neurons","pmids":["29981796","29971943","28351660","30033152"],"confidence":"High","gaps":["How the same receptor selects TRAF3IP2 vs. JAK2/STAT3 vs. ADAM17 branches per tissue is unclear","Synaptic refinement effector mechanism downstream of Fn14 undefined"]},{"year":2019,"claim":"Showed Fn14 is sufficient and necessary for injury-induced pain via NF-κB activation in sensory neurons.","evidence":"Spinal nerve ligation model with Fn14 gain- and loss-of-function and p65 nuclear translocation plus behavioral testing","pmids":["30976982"],"confidence":"Medium","gaps":["Ligand source driving neuronal Fn14 activation not identified","Downstream pain-relevant NF-κB targets not defined"]},{"year":2021,"claim":"Established ThPOK as a direct transcriptional repressor of TNFRSF12A, complementing earlier AR-mediated repression in defining the regulatory architecture of the locus.","evidence":"ChIP, luciferase reporter, and siRNA in gastric cancer cells with T cell co-culture","pmids":["34353698"],"confidence":"Medium","gaps":["Interplay between activating (c-JUN, NFAT1) and repressive (ThPOK, AR) inputs at the promoter not integrated","Mechanism of T cell regulation downstream of Fn14 not defined"]},{"year":2022,"claim":"Distinguished the hepatocyte cell-death mode driven by Fn14 as RIPK1-dependent apoptosis, refining how Fn14 kills cells in acute liver failure.","evidence":"TWEAK/Tnfrsf12a inhibition in TAA and APAP mouse models with pathway discrimination from necroptosis/pyroptosis and human biopsy validation","pmids":["35853848"],"confidence":"Medium","gaps":["Why hepatocytes use RIPK1-apoptosis vs. pyroptosis in different injuries unresolved","Direct molecular link from Fn14 to RIPK1 not defined"]},{"year":2023,"claim":"Resolved a bile-acid/c-JUN-induced pyroptotic Fn14 program and a profibrogenic hepatic progenitor program, while a myoblast study placed Fn14 upstream of Wnt/calcium signaling in muscle fusion.","evidence":"Tnfrsf12a knockout cholestasis models with ChIP and Caspase-1/GSDMD analysis, Fn14 antagonism in a biliary atresia model with organoids, and conditional myoblast knockout with Wnt rescue","pmids":["36690641","36626628","37813488"],"confidence":"High","gaps":["How Fn14 mechanistically engages the Wnt/calcium axis in myoblasts is unknown","Reconciliation of Fn14 pro-death (pyroptosis) vs. pro-proliferative (HPC) hepatic roles not provided"]},{"year":2024,"claim":"Defined a chromatin-level mechanism by which constitutive Fn14 signaling activates super-enhancers to drive NAMPT-dependent metabolic reprogramming and metastasis in TNBC.","evidence":"H3K27ac ChIP-seq, Hi-C chromatin looping, NAMPT inhibition, and in vivo xenograft metastasis with metabolic profiling","pmids":["38965263"],"confidence":"High","gaps":["The transcription factors linking Fn14/NF-κB to super-enhancer activation not fully mapped","Whether this depends on TWEAK or on self-association not resolved"]},{"year":2025,"claim":"Revealed a protective, anti-fibrotic role for Fn14 in the lung, contrasting its profibrotic role elsewhere and identifying a specific pro-regenerative macrophage subset it supports.","evidence":"Fn14 knockout in bleomycin lung fibrosis with macrophage flow cytometry, ECM quantification, and organoid co-culture","pmids":["39827460"],"confidence":"High","gaps":["Why Fn14 restrains fibroblasts in lung but activates them in heart/liver is mechanistically unexplained","Signaling branch mediating chemokine-driven macrophage recruitment not defined"]},{"year":null,"claim":"It remains unknown how a single small receptor selects among its many downstream branches (canonical vs. non-canonical NF-κB, MRTF-A, TRAF3IP2, JAK2/STAT3, RIPK1-apoptosis, pyroptosis) to produce opposing tissue outcomes ranging from fibrosis promotion to fibrosis restraint.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying structural or stoichiometric model links receptor clustering state to specific downstream branch selection","Determinants of pro- vs. anti-fibrotic outcomes across tissues not identified","TRAF-level recruitment code not experimentally defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,6]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,6]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,6,3]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[19,20]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[12,26]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[14,22]}],"complexes":[],"partners":["TWEAK","FGFR1","TRAF3IP2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NP84","full_name":"Tumor necrosis factor receptor superfamily member 12A","aliases":["Fibroblast growth factor-inducible immediate-early response protein 14","FGF-inducible 14","Tweak-receptor","TweakR"],"length_aa":129,"mass_kda":13.9,"function":"Receptor for TNFSF12/TWEAK. Weak inducer of apoptosis in some cell types. Promotes angiogenesis and the proliferation of endothelial cells. May modulate cellular adhesion to matrix proteins","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q9NP84/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFRSF12A","classification":"Not Classified","n_dependent_lines":34,"n_total_lines":1208,"dependency_fraction":0.028145695364238412},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFRSF12A","total_profiled":1310},"omim":[{"mim_id":"605914","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 12A; TNFRSF12A","url":"https://www.omim.org/entry/605914"},{"mim_id":"602695","title":"TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 12; TNFSF12","url":"https://www.omim.org/entry/602695"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TNFRSF12A"},"hgnc":{"alias_symbol":["FN14","TweakR","CD266"],"prev_symbol":[]},"alphafold":{"accession":"Q9NP84","domains":[{"cath_id":"4.10.400.20","chopping":"36-70","consensus_level":"medium","plddt":83.6606,"start":36,"end":70},{"cath_id":"1.20.5","chopping":"71-107","consensus_level":"medium","plddt":78.98,"start":71,"end":107}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NP84","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NP84-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NP84-F1-predicted_aligned_error_v6.png","plddt_mean":73.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFRSF12A","jax_strain_url":"https://www.jax.org/strain/search?query=TNFRSF12A"},"sequence":{"accession":"Q9NP84","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NP84.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NP84/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NP84"}},"corpus_meta":[{"pmid":"18404150","id":"PMC_18404150","title":"The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting.","date":"2008","source":"Nature reviews. Drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/18404150","citation_count":499,"is_preprint":false},{"pmid":"12787562","id":"PMC_12787562","title":"TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor.","date":"2003","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12787562","citation_count":254,"is_preprint":false},{"pmid":"17981048","id":"PMC_17981048","title":"TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease.","date":"2007","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/17981048","citation_count":246,"is_preprint":false},{"pmid":"22017434","id":"PMC_22017434","title":"TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses.","date":"2011","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22017434","citation_count":182,"is_preprint":false},{"pmid":"12794080","id":"PMC_12794080","title":"TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12794080","citation_count":132,"is_preprint":false},{"pmid":"26359988","id":"PMC_26359988","title":"Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26359988","citation_count":128,"is_preprint":false},{"pmid":"20844036","id":"PMC_20844036","title":"Regulation of tumor necrosis factor-like weak inducer of apoptosis receptor protein (TWEAKR) expression by Kaposi's sarcoma-associated herpesvirus microRNA prevents TWEAK-induced apoptosis and inflammatory cytokine expression.","date":"2010","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/20844036","citation_count":115,"is_preprint":false},{"pmid":"15353286","id":"PMC_15353286","title":"The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity.","date":"2004","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/15353286","citation_count":97,"is_preprint":false},{"pmid":"19629561","id":"PMC_19629561","title":"FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK.","date":"2009","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/19629561","citation_count":97,"is_preprint":false},{"pmid":"24400009","id":"PMC_24400009","title":"Neuropsychiatric Lupus, the Blood Brain Barrier, and the TWEAK/Fn14 Pathway.","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24400009","citation_count":80,"is_preprint":false},{"pmid":"24636536","id":"PMC_24636536","title":"TWEAK/Fn14 axis: the current paradigm of tissue injury-inducible function in the midst of complexities.","date":"2014","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24636536","citation_count":79,"is_preprint":false},{"pmid":"23957828","id":"PMC_23957828","title":"The TWEAK-Fn14 system as a potential drug target.","date":"2013","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23957828","citation_count":78,"is_preprint":false},{"pmid":"23325387","id":"PMC_23325387","title":"Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction.","date":"2013","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/23325387","citation_count":67,"is_preprint":false},{"pmid":"23320797","id":"PMC_23320797","title":"TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier.","date":"2013","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/23320797","citation_count":67,"is_preprint":false},{"pmid":"26300004","id":"PMC_26300004","title":"The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26300004","citation_count":63,"is_preprint":false},{"pmid":"24478772","id":"PMC_24478772","title":"TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24478772","citation_count":61,"is_preprint":false},{"pmid":"24478779","id":"PMC_24478779","title":"TWEAK/Fn14 Signaling Axis Mediates Skeletal Muscle Atrophy and Metabolic Dysfunction.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24478779","citation_count":60,"is_preprint":false},{"pmid":"33221352","id":"PMC_33221352","title":"TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression.","date":"2020","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/33221352","citation_count":58,"is_preprint":false},{"pmid":"34542797","id":"PMC_34542797","title":"The TWEAK/Fn14/CD163 axis-implications for metabolic disease.","date":"2021","source":"Reviews in endocrine & metabolic disorders","url":"https://pubmed.ncbi.nlm.nih.gov/34542797","citation_count":58,"is_preprint":false},{"pmid":"24444596","id":"PMC_24444596","title":"The TWEAK-Fn14 pathway: a potent regulator of skeletal muscle biology in health and disease.","date":"2013","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/24444596","citation_count":58,"is_preprint":false},{"pmid":"18483204","id":"PMC_18483204","title":"No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies.","date":"2008","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/18483204","citation_count":58,"is_preprint":false},{"pmid":"21586630","id":"PMC_21586630","title":"Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.","date":"2011","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/21586630","citation_count":58,"is_preprint":false},{"pmid":"28639899","id":"PMC_28639899","title":"TWEAK/Fn14 signaling in tumors.","date":"2017","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28639899","citation_count":57,"is_preprint":false},{"pmid":"22672874","id":"PMC_22672874","title":"The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases.","date":"2012","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/22672874","citation_count":57,"is_preprint":false},{"pmid":"15885893","id":"PMC_15885893","title":"TWEAK and Fn14: new molecular targets for cancer therapy?","date":"2006","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15885893","citation_count":57,"is_preprint":false},{"pmid":"30033152","id":"PMC_30033152","title":"Visual Experience-Dependent Expression of Fn14 Is Required for Retinogeniculate Refinement.","date":"2018","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/30033152","citation_count":56,"is_preprint":false},{"pmid":"29038621","id":"PMC_29038621","title":"TWEAK/Fn14 Activation Participates in Skin Inflammation.","date":"2017","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/29038621","citation_count":54,"is_preprint":false},{"pmid":"30014744","id":"PMC_30014744","title":"miR-149-5p inhibits cell growth by regulating TWEAK/Fn14/PI3K/AKT pathway and predicts favorable survival in human osteosarcoma.","date":"2018","source":"International journal of immunopathology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30014744","citation_count":52,"is_preprint":false},{"pmid":"24339827","id":"PMC_24339827","title":"TWEAK/Fn14 and Non-Canonical NF-kappaB Signaling in Kidney Disease.","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24339827","citation_count":51,"is_preprint":false},{"pmid":"18793781","id":"PMC_18793781","title":"Induction of the cytokine TWEAK and its receptor Fn14 in ischemic stroke.","date":"2008","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/18793781","citation_count":51,"is_preprint":false},{"pmid":"12821115","id":"PMC_12821115","title":"Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12821115","citation_count":51,"is_preprint":false},{"pmid":"19018248","id":"PMC_19018248","title":"Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain: implications for inflammatory tissue injury.","date":"2008","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19018248","citation_count":51,"is_preprint":false},{"pmid":"29326686","id":"PMC_29326686","title":"Regulation of Fn14 Receptor and NF-κB Underlies Inflammation in Meniere's Disease.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29326686","citation_count":50,"is_preprint":false},{"pmid":"17127278","id":"PMC_17127278","title":"Role of TWEAK and Fn14 in tumor biology.","date":"2007","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17127278","citation_count":48,"is_preprint":false},{"pmid":"24970477","id":"PMC_24970477","title":"AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24970477","citation_count":48,"is_preprint":false},{"pmid":"23190886","id":"PMC_23190886","title":"The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.","date":"2012","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/23190886","citation_count":47,"is_preprint":false},{"pmid":"19762780","id":"PMC_19762780","title":"Fn14-Fc fusion protein regulates atherosclerosis in ApoE-/- mice and inhibits macrophage lipid uptake in vitro.","date":"2009","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19762780","citation_count":47,"is_preprint":false},{"pmid":"33000480","id":"PMC_33000480","title":"TWEAK/Fn14 axis is an important player in fibrosis.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33000480","citation_count":45,"is_preprint":false},{"pmid":"17485328","id":"PMC_17485328","title":"TWEAK and Fn14. New players in the pathogenesis of atherosclerosis.","date":"2007","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17485328","citation_count":45,"is_preprint":false},{"pmid":"16503147","id":"PMC_16503147","title":"Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity.","date":"2006","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/16503147","citation_count":45,"is_preprint":false},{"pmid":"23999007","id":"PMC_23999007","title":"Fn14 in podocytes and proteinuric kidney disease.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23999007","citation_count":44,"is_preprint":false},{"pmid":"28351660","id":"PMC_28351660","title":"TWEAK/Fn14 Activation Contributes to the Pathogenesis of Bullous Pemphigoid.","date":"2017","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28351660","citation_count":43,"is_preprint":false},{"pmid":"26264384","id":"PMC_26264384","title":"TWEAK/Fn14 activation induces keratinocyte proliferation under psoriatic inflammation.","date":"2015","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/26264384","citation_count":41,"is_preprint":false},{"pmid":"28411440","id":"PMC_28411440","title":"TWEAK/Fn14 promotes pro-inflammatory cytokine secretion in hepatic stellate cells via NF-κB/STAT3 pathways.","date":"2017","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28411440","citation_count":41,"is_preprint":false},{"pmid":"20189297","id":"PMC_20189297","title":"TWEAK/Fn14 promotes apoptosis of human endometrial cancer cells via caspase pathway.","date":"2010","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/20189297","citation_count":41,"is_preprint":false},{"pmid":"23750247","id":"PMC_23750247","title":"TWEAK-independent Fn14 self-association and NF-κB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domain.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23750247","citation_count":40,"is_preprint":false},{"pmid":"21435232","id":"PMC_21435232","title":"TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis.","date":"2011","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21435232","citation_count":40,"is_preprint":false},{"pmid":"23532848","id":"PMC_23532848","title":"Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23532848","citation_count":38,"is_preprint":false},{"pmid":"29981796","id":"PMC_29981796","title":"TRAF3IP2 mediates TWEAK/TWEAKR-induced pro-fibrotic responses in cultured cardiac fibroblasts and the heart.","date":"2018","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/29981796","citation_count":36,"is_preprint":false},{"pmid":"24469836","id":"PMC_24469836","title":"Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.","date":"2014","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/24469836","citation_count":36,"is_preprint":false},{"pmid":"30081003","id":"PMC_30081003","title":"TWEAK/Fn14 Signals Mediate Burn Wound Repair.","date":"2018","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/30081003","citation_count":35,"is_preprint":false},{"pmid":"24611063","id":"PMC_24611063","title":"TWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac Failure.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24611063","citation_count":35,"is_preprint":false},{"pmid":"26659091","id":"PMC_26659091","title":"Role of the TWEAK/Fn14 pathway in autoimmune diseases.","date":"2016","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/26659091","citation_count":35,"is_preprint":false},{"pmid":"23288170","id":"PMC_23288170","title":"HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes.","date":"2013","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23288170","citation_count":35,"is_preprint":false},{"pmid":"24446436","id":"PMC_24446436","title":"The expression of Fn14 via mechanical stress-activated JNK contributes to apoptosis induction in osteoblasts.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24446436","citation_count":35,"is_preprint":false},{"pmid":"29681850","id":"PMC_29681850","title":"Tnfrsf12a-Mediated Atherosclerosis Signaling and Inflammatory Response as a Common Protection Mechanism of Shuxuening Injection Against Both Myocardial and Cerebral Ischemia-Reperfusion Injuries.","date":"2018","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29681850","citation_count":34,"is_preprint":false},{"pmid":"36690641","id":"PMC_36690641","title":"Hepatic TNFRSF12A promotes bile acid-induced hepatocyte pyroptosis through NFκB/Caspase-1/GSDMD signaling in cholestasis.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/36690641","citation_count":33,"is_preprint":false},{"pmid":"25504044","id":"PMC_25504044","title":"TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25504044","citation_count":33,"is_preprint":false},{"pmid":"32526219","id":"PMC_32526219","title":"TWEAK/Fn14 axis in respiratory diseases.","date":"2020","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32526219","citation_count":31,"is_preprint":false},{"pmid":"29201025","id":"PMC_29201025","title":"Regulation of Neuroinflammation: What Role for the Tumor Necrosis Factor-Like Weak Inducer of Apoptosis/Fn14 Pathway?","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29201025","citation_count":31,"is_preprint":false},{"pmid":"34646379","id":"PMC_34646379","title":"Interruption of neutrophil extracellular traps formation dictates host defense and tubular HOXA5 stability to augment efficacy of anti-Fn14 therapy against septic AKI.","date":"2021","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/34646379","citation_count":30,"is_preprint":false},{"pmid":"30038329","id":"PMC_30038329","title":"Fn14 deficiency ameliorates psoriasis-like skin disease in a murine model.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30038329","citation_count":30,"is_preprint":false},{"pmid":"27339384","id":"PMC_27339384","title":"Out of the TWEAKlight: Elucidating the Role of Fn14 and TWEAK in Acute Kidney Injury.","date":"2016","source":"Seminars in nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/27339384","citation_count":30,"is_preprint":false},{"pmid":"24376672","id":"PMC_24376672","title":"BAFF, APRIL, TWEAK, BCMA, TACI and Fn14 proteins are related to human glioma tumor grade: immunohistochemistry and public microarray data meta-analysis.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24376672","citation_count":30,"is_preprint":false},{"pmid":"23073510","id":"PMC_23073510","title":"Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb.","date":"2012","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23073510","citation_count":29,"is_preprint":false},{"pmid":"26012567","id":"PMC_26012567","title":"Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26012567","citation_count":29,"is_preprint":false},{"pmid":"24337061","id":"PMC_24337061","title":"TWEAK/Fn14 signaling mediates gastric cancer cell resistance to 5-fluorouracil via NF-κB activation.","date":"2013","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24337061","citation_count":28,"is_preprint":false},{"pmid":"32200423","id":"PMC_32200423","title":"Controversies in TWEAK-Fn14 signaling in skeletal muscle atrophy and regeneration.","date":"2020","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/32200423","citation_count":27,"is_preprint":false},{"pmid":"24408972","id":"PMC_24408972","title":"TWEAK/Fn14 pathway is a novel mediator of retinal neovascularization.","date":"2014","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/24408972","citation_count":27,"is_preprint":false},{"pmid":"24571920","id":"PMC_24571920","title":"FGF1-mediated cardiomyocyte cell cycle reentry depends on the interaction of FGFR-1 and Fn14.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/24571920","citation_count":27,"is_preprint":false},{"pmid":"24273541","id":"PMC_24273541","title":"TWEAK and Fn14 in the Neurovascular Unit.","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24273541","citation_count":26,"is_preprint":false},{"pmid":"34595061","id":"PMC_34595061","title":"Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma.","date":"2021","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/34595061","citation_count":26,"is_preprint":false},{"pmid":"29971943","id":"PMC_29971943","title":"TWEAK/Fn14 mediates atrial-derived HL-1 myocytes hypertrophy via JAK2/STAT3 signalling pathway.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29971943","citation_count":26,"is_preprint":false},{"pmid":"23469193","id":"PMC_23469193","title":"Functional expression of TWEAK and the receptor Fn14 in human malignant ovarian tumors: possible implication for ovarian tumor intervention.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23469193","citation_count":26,"is_preprint":false},{"pmid":"33512736","id":"PMC_33512736","title":"TWEAK-Fn14 as a common pathway in the heart and the kidneys in cardiorenal syndrome.","date":"2021","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33512736","citation_count":25,"is_preprint":false},{"pmid":"28138696","id":"PMC_28138696","title":"Knockdown of the differentially expressed gene TNFRSF12A inhibits hepatocellular carcinoma cell proliferation and migration in vitro.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28138696","citation_count":25,"is_preprint":false},{"pmid":"36626628","id":"PMC_36626628","title":"TWEAK/FN14 promotes profibrogenic pathway activation in Prominin-1-expressing hepatic progenitor cells in biliary atresia.","date":"2023","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/36626628","citation_count":24,"is_preprint":false},{"pmid":"17485258","id":"PMC_17485258","title":"Tweak and FN14 in central nervous system health and disease.","date":"2007","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17485258","citation_count":23,"is_preprint":false},{"pmid":"25239934","id":"PMC_25239934","title":"Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.","date":"2014","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25239934","citation_count":23,"is_preprint":false},{"pmid":"27171494","id":"PMC_27171494","title":"Soluble Fn14 Is Detected and Elevated in Mouse and Human Kidney Disease.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27171494","citation_count":22,"is_preprint":false},{"pmid":"23443741","id":"PMC_23443741","title":"Expression of TWEAK/Fn14 in neuroblastoma: implications in tumorigenesis.","date":"2013","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23443741","citation_count":22,"is_preprint":false},{"pmid":"38965263","id":"PMC_38965263","title":"TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38965263","citation_count":21,"is_preprint":false},{"pmid":"29257217","id":"PMC_29257217","title":"TWEAK/Fn14 promotes oxidative stress through AMPK/PGC‑1α/MnSOD signaling pathway in endothelial cells.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/29257217","citation_count":21,"is_preprint":false},{"pmid":"33886003","id":"PMC_33886003","title":"Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy.","date":"2021","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33886003","citation_count":20,"is_preprint":false},{"pmid":"22767506","id":"PMC_22767506","title":"Lipocalin 2, the TNF-like receptor TWEAKR and its ligand TWEAK act downstream of NFAT1 to regulate breast cancer cell invasion.","date":"2012","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22767506","citation_count":20,"is_preprint":false},{"pmid":"30414907","id":"PMC_30414907","title":"TWEAK/Fn14 Interaction Confers Aggressive Properties to Cutaneous Squamous Cell Carcinoma.","date":"2018","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/30414907","citation_count":20,"is_preprint":false},{"pmid":"29266762","id":"PMC_29266762","title":"The TWEAK/Fn14 pathway is required for calcineurin inhibitor toxicity of the kidneys.","date":"2018","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/29266762","citation_count":20,"is_preprint":false},{"pmid":"30976982","id":"PMC_30976982","title":"Fn14 Participates in Neuropathic Pain Through NF-κB Pathway in Primary Sensory Neurons.","date":"2019","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30976982","citation_count":20,"is_preprint":false},{"pmid":"22752727","id":"PMC_22752727","title":"The role of TWEAK/Fn14 in cardiac remodeling.","date":"2012","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/22752727","citation_count":20,"is_preprint":false},{"pmid":"39178365","id":"PMC_39178365","title":"Integrative single-cell and spatial transcriptomic analyses identify a pathogenic cholangiocyte niche and TNFRSF12A as therapeutic target for biliary atresia.","date":"2024","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/39178365","citation_count":19,"is_preprint":false},{"pmid":"35853848","id":"PMC_35853848","title":"Inhibition of TWEAK/Tnfrsf12a axis protects against acute liver failure by suppressing RIPK1-dependent apoptosis.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35853848","citation_count":19,"is_preprint":false},{"pmid":"34353698","id":"PMC_34353698","title":"ThPOK transcriptionally inactivates TNFRSF12A to increase the proliferation of T cells with the involvement of the NF-kB pathway.","date":"2021","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/34353698","citation_count":19,"is_preprint":false},{"pmid":"36214671","id":"PMC_36214671","title":"TWEAK-Fn14-RelB Signaling Cascade Promotes Stem Cell-like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse.","date":"2023","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/36214671","citation_count":19,"is_preprint":false},{"pmid":"39827460","id":"PMC_39827460","title":"TWEAK-Fn14 signaling protects mice from pulmonary fibrosis by inhibiting fibroblast activation and recruiting pro-regenerative macrophages.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39827460","citation_count":18,"is_preprint":false},{"pmid":"36339601","id":"PMC_36339601","title":"Targeting fibroblast growth factor (FGF)-inducible 14 (Fn14) for tumor therapy.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36339601","citation_count":18,"is_preprint":false},{"pmid":"28744451","id":"PMC_28744451","title":"Lipopolysaccharide Upregulated Intestinal Epithelial Cell Expression of Fn14 and Activation of Fn14 Signaling Amplify Intestinal TLR4-Mediated Inflammation.","date":"2017","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/28744451","citation_count":18,"is_preprint":false},{"pmid":"37813488","id":"PMC_37813488","title":"Fn14 promotes myoblast fusion during regenerative myogenesis.","date":"2023","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/37813488","citation_count":17,"is_preprint":false},{"pmid":"24710956","id":"PMC_24710956","title":"FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion.","date":"2014","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/24710956","citation_count":17,"is_preprint":false},{"pmid":"24130833","id":"PMC_24130833","title":"Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24130833","citation_count":17,"is_preprint":false},{"pmid":"28455246","id":"PMC_28455246","title":"Fn14·TRAIL fusion protein is oligomerized by TWEAK into a superefficient TRAIL analog.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28455246","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50749,"output_tokens":8902,"usd":0.142889,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19281,"output_tokens":5747,"usd":0.12004,"stage2_stop_reason":"end_turn"},"total_usd":0.262929,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"TWEAK binds Fn14 (TNFRSF12A) with physiological affinity; Fn14 is the cognate receptor for TWEAK and is a type I transmembrane protein and the smallest known TNFR superfamily member. Fn14 signals via recruitment of TNFR-associated factors (TRAFs).\",\n      \"method\": \"Receptor-ligand binding assays, cDNA cloning, transfection studies\",\n      \"journal\": \"Cytokine & growth factor reviews\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — foundational receptor identification, replicated across multiple labs and review papers, consistent with the entire corpus\",\n      \"pmids\": [\"12787562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TWEAK-induced osteoclast differentiation of RAW264.7 macrophages is not mediated by Fn14/TweakR (no Fn14 surface expression detected by flow cytometry; Fn14-neutralizing antibodies did not block the effect), suggesting a second TWEAK receptor (TweakR2) exists on these cells. In contrast, TWEAK binding to Fn14 in HT-29 cells activated NF-κB and JNK but only weakly activated MAPK, whereas TweakR2 activated NF-κB, MAPK and JNK.\",\n      \"method\": \"Flow cytometry, neutralizing antibodies, cell differentiation assays, signaling pathway analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single lab with multiple methods but the second receptor was never molecularly identified\",\n      \"pmids\": [\"12794080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Recombinant murine TWEAK bound to murine Fn14-transfected cells and induced cell death. Anti-Fn14 monoclonal antibodies cross-reacting with murine Fn14 also induced cell death in Fn14-transfected cells. Peritoneal macrophages secreted soluble functional TWEAK that was cytotoxic to Fn14-expressing cells.\",\n      \"method\": \"cDNA transfection, monoclonal antibody generation, cytotoxicity assays, functional neutralization\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ligand-receptor functional assay in transfected cells, reciprocal antibody blocking, single lab\",\n      \"pmids\": [\"12821115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Fn14 expression in cardiomyocytes is induced by FGF1, norepinephrine, angiotensin II, and mechanical stretch via the RhoA/ROCK kinase pathway; C3 exoenzyme (RhoA inhibitor), Y27632 (ROCK inhibitor), and siRNA knockdown of RhoA/ROCK each abolished Fn14 upregulation. TWEAK stimulation of Fn14-expressing cardiomyocytes promoted nuclear translocation of NF-κB and induced NF-κB-dependent genes (RANTES, MCP-1); siRNA knockdown of Fn14 inhibited TWEAK-induced NF-κB activation.\",\n      \"method\": \"siRNA knockdown, pharmacological inhibitors (C3 exoenzyme, Y27632), NF-κB nuclear translocation assay, neonatal rat cardiomyocyte culture\",\n      \"journal\": \"Basic research in cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (pharmacological + genetic inhibition), single lab\",\n      \"pmids\": [\"19629561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Fn14 activation induces collagen expression in cardiac fibroblasts via RhoA-dependent nuclear translocation of myocardin-related transcription factor-A (MRTF-A/MAL). Fn14 activation also caused fibroblast proliferation and myofibroblast differentiation. Fn14 knockout mice showed substantially reduced RV fibrosis and dysfunction after pulmonary artery banding. Fn14 expression in cardiac fibroblasts is regulated by endothelin-1.\",\n      \"method\": \"Fn14 knockout mice, cell culture activation assays, RhoA/MRTF-A pathway analysis, histology\",\n      \"journal\": \"Basic research in cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout mouse model with defined phenotype plus mechanistic pathway (RhoA/MRTF-A/collagen) validated in vitro, multiple orthogonal methods\",\n      \"pmids\": [\"23325387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Fn14 can self-associate into dimers independently of TWEAK binding; an 18-amino acid region within the Fn14 cytoplasmic domain mediates self-association. Dimerization occurs via an intermolecular disulfide bond at cysteine residue 122. A TWEAK-binding-deficient Fn14 deletion mutant retains the ability to activate the NF-κB pathway, demonstrating TWEAK-independent Fn14 signaling. Both endogenous and overexpressed Fn14 were detected in dimeric form under non-reducing SDS-PAGE.\",\n      \"method\": \"Deletion mutagenesis, non-reducing SDS-PAGE, NF-κB reporter assay in transfected cells, site-directed mutagenesis of Cys122\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis combined with biochemical dimerization assay and functional NF-κB readout, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"23750247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Anti-Fn14 monoclonal antibodies (PDL192, P4A8) selectively activate the alternative (non-canonical) NF-κB pathway but do not activate classical NF-κB, IL-8 production, or cell death. Oligomerization of anti-Fn14 antibodies (via protein G or FcγR binding) converts them into full agonists mimicking membrane TWEAK, activating both classical and alternative NF-κB pathways. Soluble TWEAK predominantly triggers the alternative NF-κB pathway, while membrane-bound TWEAK triggers all Fn14-associated pathways. This indicates the alternative NF-κB pathway responds to Fn14 dimerization alone.\",\n      \"method\": \"NF-κB reporter assays, IL-8 ELISA, cell death assays, antibody oligomerization with protein G, FcγR-mediated cross-linking\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple functional assays with defined mechanistic controls dissecting canonical vs. non-canonical NF-κB; antibody oligomerization experiments functionally discriminate signaling thresholds; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"23532848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FGF receptor-1 (FGFR-1) physically interacts with Fn14 in cardiomyocytes, as shown by co-immunoprecipitation and proximity ligation assay. This interaction is enhanced by their respective ligands FGF1 and TWEAK. FGF1-induced cardiomyocyte cell cycle reentry is blocked by Fn14 inhibition, and TWEAK-induced cell cycle activation is blocked by FGFR-1 signaling inhibition. Co-stimulation with FGF1 and TWEAK synergistically promotes cell cycle reentry via PI3K/Akt signaling.\",\n      \"method\": \"Co-immunoprecipitation, proximity ligation assay, cell cycle assays with pharmacological and genetic inhibition, PI3K/Akt pathway analysis\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — physical interaction confirmed by two independent methods (Co-IP and PLA) plus functional epistasis experiments, single lab\",\n      \"pmids\": [\"24571920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Large-magnitude (12%) cyclic stretch induces Ca2+ influx and reactive oxygen species generation in osteoblasts, activating ASK1-JNK pathways, which transiently upregulate Fn14 gene expression. Cells with elevated Fn14 become sensitive to TWEAK-induced apoptosis. Small-magnitude (1%) stretch activates ERK and osteogenic gene expression, which is suppressed by JNK activated at high stretch.\",\n      \"method\": \"Cyclic stretch application, calcium imaging, ROS assays, gene expression analysis, JNK/p38 pathway inhibition, primary osteoblast validation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined mechanistic pathway (stretch→Ca2+→ROS→ASK1→JNK→Fn14 upregulation→TWEAK sensitivity) with multiple methods, single lab\",\n      \"pmids\": [\"24446436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Fn14 depletion inhibits bone metastasis in prostate cancer experimental models; functional reconstitution of Fn14 with constitutively active IKKβ rescues this phenotype, placing Fn14 upstream of IKKβ-dependent NF-κB signaling in bone metastasis. Androgen receptor (AR) binding to the Fn14 enhancer decreases Fn14 expression, establishing AR as a transcriptional repressor of Fn14.\",\n      \"method\": \"Fn14 siRNA depletion, IKKβ reconstitution, chromatin immunoprecipitation (AR binding to Fn14 enhancer), in vivo bone metastasis models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (IKKβ reconstitution) and ChIP for upstream regulation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"24970477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Fn14 knockout in mice with RNA toxicity (myotonic dystrophy model) results in reduced muscle pathology and improved function. Anti-TWEAK antibody treatment similarly improved muscle histopathology and function. Fn14 induction in skeletal muscle correlates with NF-κB pathway activation in this disease context.\",\n      \"method\": \"Fn14 knockout mice, anti-TWEAK antibody treatment, muscle histopathology, functional assays, NF-κB pathway analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout and pharmacological antibody blocking converge on the same phenotypic rescue in vivo, demonstrating causal role of Fn14 in disease muscle pathology\",\n      \"pmids\": [\"25504044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Fn14 expression in tumor cells (rather than host cells) is required for cancer-induced cachexia; tumors in Fn14-deficient or TWEAK-deficient hosts still cause cachexia comparable to wild-type mice, while anti-Fn14 antibodies targeting tumor Fn14 prevented tumor-induced inflammation and loss of fat and muscle mass, extending lifespan.\",\n      \"method\": \"Fn14-knockout and TWEAK-knockout mouse hosts with tumor transplantation, anti-Fn14 antibody treatment, body composition analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic host knockout demonstrates tumor-cell-autonomous Fn14 requirement; antibody intervention confirms functional necessity; multiple orthogonal approaches in single high-impact study\",\n      \"pmids\": [\"26359988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TWEAK/Fn14 activation in hepatic stellate cells (LX-2 cells) promotes pro-inflammatory cytokine secretion (IL-8, IL-6, RANTES, MCP-1) via activation of NF-κB and STAT3 pathways. NF-κB and STAT3 interact with each other in this context, synergistically amplifying cytokine secretion. Fn14 siRNA knockdown inhibited these effects.\",\n      \"method\": \"ELISA, RT-PCR, Western blotting of pathway components, siRNA knockdown, co-immunoprecipitation of NF-κB/STAT3 interaction\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with multiple pathway readouts plus Co-IP of NF-κB/STAT3 interaction, single lab\",\n      \"pmids\": [\"28411440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TRAF3IP2 (TRAF3 Interacting Protein 2) mediates TWEAK/Fn14-induced pro-fibrotic responses in cardiac fibroblasts. TWEAK upregulates TRAF3IP2 expression and promotes its nuclear translocation. Silencing TRAF3IP2 inhibited TWEAK-induced p38 MAPK, NF-κB and AP-1 activation, inflammatory cytokine expression, MMP/TIMP1 activation, collagen secretion, and fibroblast proliferation/migration. TRAF3IP2 knockout mice were protected from TWEAK-induced cardiac fibrosis and dysfunction in vivo.\",\n      \"method\": \"siRNA knockdown, TRAF3IP2 knockout mice, TWEAK infusion model, Western blotting, cardiac function assessment\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout in vivo combined with siRNA epistasis in vitro with multiple mechanistic readouts; TRAF3IP2 placed as causal downstream mediator of Fn14 signaling\",\n      \"pmids\": [\"29981796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Visual experience induces Fn14 expression in excitatory thalamocortical neurons of the dorsal lateral geniculate nucleus. Fn14 knockout mice show deficits specifically in experience-dependent (not spontaneous activity-dependent) retinogeniculate refinement, with functionally weaker and structurally smaller retinogeniculate inputs, establishing Fn14 as a molecular link between sensory-driven gene expression and synaptic refinement.\",\n      \"method\": \"Single-nucleus RNA sequencing, Fn14 knockout mice, electrophysiology, structural synapse analysis\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout mouse with electrophysiological and structural readouts plus single-nucleus transcriptomics identifying cell-type-specific expression; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"30033152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TWEAK/Fn14 activation in atrial myocytes mediates hypertrophy partly through the JAK2/STAT3 signaling pathway; siRNA inhibition of JAK2 or STAT3 attenuated TWEAK-induced HL-1 atrial myocyte hypertrophy. Fn14 knockdown counteracted TWEAK-induced increases in ANP and Troponin T.\",\n      \"method\": \"siRNA knockdown of Fn14, JAK2, and STAT3; measurement of hypertrophy markers (ANP, Troponin T, cell size)\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA pathway epistasis with multiple hypertrophy markers, single lab\",\n      \"pmids\": [\"29971943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TWEAK/Fn14 activation in keratinocytes promotes BP180 loss and reduced cell adhesion via activation of ERK and NF-κB pathways and downstream ADAM17. siRNA silencing of ADAM17 blocked TWEAK-induced BP180 loss, placing ADAM17 downstream of Fn14 signaling in this context. Fn14 siRNA preserved BP180 expression and protected cells from losing adherence.\",\n      \"method\": \"siRNA knockdown of Fn14 and ADAM17, Western blotting of ERK and NF-κB, cell adhesion assays\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA epistasis identifying ADAM17 as downstream effector, multiple pathway readouts, single lab\",\n      \"pmids\": [\"28351660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Fn14 expression is increased in dorsal root ganglion (DRG) neurons following peripheral nerve injury. Blocking Fn14 increase attenuated SNL-induced pain hypersensitivity. Conversely, mimicking Fn14 increase produced pain hypersensitivity in the absence of injury. Mechanistically, increased Fn14 activated the NF-κB pathway through promoting p65 nuclear translocation in injured DRG neurons.\",\n      \"method\": \"Spinal nerve ligation model, Fn14 siRNA knockdown, Fn14 overexpression, NF-κB p65 nuclear translocation assay, behavioral pain testing\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with mechanistic NF-κB readout in primary neurons, single lab\",\n      \"pmids\": [\"30976982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ThPOK (ZBTB7B) functions as a transcriptional repressor of TNFRSF12A (Fn14) by binding directly to the TNFRSF12A promoter. ThPOK knockdown elevated TNFRSF12A levels in gastric cancer cells. TNFRSF12A activates the NF-κB pathway and regulates T cell proliferation in a gastric cancer co-culture context.\",\n      \"method\": \"ChIP (ThPOK binding to TNFRSF12A promoter), siRNA knockdown, luciferase reporter, NF-κB pathway analysis, T cell co-culture assays\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms direct promoter binding; functional readouts with siRNA, single lab\",\n      \"pmids\": [\"34353698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Bile acids induce TNFRSF12A expression by enhancing c-JUN transcription factor binding to the TNFRSF12A promoter. TNFRSF12A then initiates hepatocyte pyroptosis via NFκB/Caspase-1/GSDMD signaling. Genetic ablation of Tnfrsf12a in cholestatic mice significantly reduced hepatocyte pyroptosis and cholestatic liver injury. TWEAK from infiltrated macrophages enhanced TNFRSF12A-induced hepatocyte pyroptosis.\",\n      \"method\": \"Tnfrsf12a knockout mice (BDL and DDC models), ChIP assay (c-JUN binding), Western blotting (Caspase-1, GSDMD cleavage), primary hepatocyte culture, human liver tissue samples\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — genetic knockout with defined pyroptosis phenotype plus ChIP for upstream transcriptional regulation and biochemical pathway characterization, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"36690641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TWEAK/Tnfrsf12a axis activates RIPK1-dependent apoptosis (not necroptosis or pyroptosis) in hepatocytes during acute liver failure. Inhibition of the TWEAK/Tnfrsf12a axis markedly attenuated acute liver failure in TAA and APAP models. This distinguishes Tnfrsf12a-induced cell death mechanism in hepatocytes as RIPK1-dependent apoptosis.\",\n      \"method\": \"Tnfrsf12a inhibition, TAA and APAP liver failure mouse models, RIPK1 pathway analysis, discrimination from necroptosis/pyroptosis by specific pathway inhibitors, human liver biopsy validation\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined mechanistic cell death pathway with pharmacological inhibition in two independent mouse models, single lab\",\n      \"pmids\": [\"35853848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Fn14 is expressed by Prominin-1 (Prom1)-expressing hepatic progenitor cells (HPCs). TWEAK/Fn14 signaling promotes HPC proliferation and profibrogenic ductular reactions; Fn14 antagonism decreased ductular reactions, biliary fibrosis, periportal fibroblast activation, and noncanonical NF-κB signaling in a mouse model of biliary atresia. Recombinant TWEAK accelerated organoid growth, blocked by Fn14 antagonist.\",\n      \"method\": \"Fn14 antagonist treatment in RRV biliary atresia model, HPC organoid assays, CRISPR-based analysis, NF-κB signaling pathway analysis, RNA sequencing\",\n      \"journal\": \"Hepatology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological Fn14 blockade in vivo plus organoid gain/loss-of-function assays with mechanistic pathway readout, single lab\",\n      \"pmids\": [\"36626628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Fn14 promotes myoblast fusion during skeletal muscle regeneration. Conditional deletion of Fn14 in myoblasts (but not differentiated myofibers) impairs muscle regeneration. Fn14 overexpression in myoblasts increases myotube diameter. Fn14 deletion reduces canonical Wnt and calcium signaling components; forced Wnt activation rescues fusion defects in Fn14-deficient myoblasts, placing Fn14 upstream of Wnt signaling in myoblast fusion.\",\n      \"method\": \"Conditional Fn14 knockout in myoblasts, global Fn14 knockout mice, Fn14 overexpression, muscle injury/regeneration model, Wnt pathway rescue experiments, in vitro differentiation assays\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional knockout distinguishes myoblast-autonomous function; Wnt pathway rescue provides epistatic placement; multiple orthogonal in vivo and in vitro methods\",\n      \"pmids\": [\"37813488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Constitutive Fn14 signaling in TNBC rewires the transcriptomic and epigenomic landscape, activating TNBC-specific super-enhancers (SEs) via chromatin looping to drive transcription of cancer dependency genes. One SE-driven target is NAMPT, whose upregulation promotes NAD+/ATP metabolic reprogramming critical for filopodia formation and metastasis.\",\n      \"method\": \"Fn14 overexpression/knockdown, H3K27ac ChIP-seq (super-enhancer mapping), Hi-C chromatin looping, NAMPT inhibition, in vivo xenograft metastasis models, metabolic profiling\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — chromatin-level mechanistic dissection (ChIP-seq + Hi-C) with functional NAMPT-metabolic-metastasis axis validated in vivo, multiple orthogonal methods in single study\",\n      \"pmids\": [\"38965263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TWEAK-Fn14 signaling in lung fibroblasts/myofibroblasts inhibits fibroblast activation and ECM synthesis, and induces chemokine expression to recruit monocytes/macrophages. Fn14 deficiency increases ECM production, impairs macrophage infiltration/differentiation, and exacerbates bleomycin-induced lung fibrosis. Fn14 deficiency specifically diminishes an injury-induced SiglecF- CD11b- MHCIIlo intermediate macrophage subpopulation that promotes AT2 cell proliferation in organoids, indicating a protective role for Fn14 signaling in pulmonary fibrosis.\",\n      \"method\": \"Fn14 knockout mice, bleomycin lung fibrosis model, macrophage flow cytometry, organoid co-culture, ECM quantification\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with mechanistic dissection of macrophage subtype and organoid functional readout, multiple orthogonal methods identifying a protective (not pathological) role of Fn14 in pulmonary fibrosis\",\n      \"pmids\": [\"39827460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Soluble TWEAK induced surface expression of RANKL by human immature STRO-1+ osteoblasts, establishing a mechanism by which TWEAK/Fn14 signaling could promote bone erosion indirectly through osteoblast-mediated osteoclastogenesis. Direct stimulation of PBMC by sTWEAK did not stimulate osteoclast formation.\",\n      \"method\": \"Flow cytometry for RANKL surface expression on osteoblasts, osteoclastogenesis assays from PBMC\",\n      \"journal\": \"Arthritis research & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single functional assay demonstrating TWEAK-induced RANKL upregulation on osteoblasts; negative result for direct osteoclastogenesis informs the mechanism\",\n      \"pmids\": [\"21435232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TWEAK increased HMGB1 mRNA expression and protein secretion in monocytes via Fn14/NF-κB and PI3K signaling; blocking anti-Fn14 antibody or NF-κB/PI3K inhibitors reversed this effect. TWEAK-mediated HMGB1 increase was only observed in M1 macrophages, not M2 macrophages. TWEAK-induced MCP-1 secretion was blocked by HMGB1 siRNA, placing HMGB1 downstream of Fn14 in MCP-1 production.\",\n      \"method\": \"Anti-Fn14 blocking antibody, NF-κB and PI3K inhibitors, HMGB1 siRNA, ELISA, in vivo TWEAK injection and TWEAK-blocking antibodies in ApoE-/- mice\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and siRNA epistasis with in vivo validation, single lab\",\n      \"pmids\": [\"23288170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TWEAK acting on Fn14 induces apoptosis in endometrial cancer cells via caspase pathways, decreasing cell viability.\",\n      \"method\": \"Caspase activation assays, cell viability assays with recombinant TWEAK treatment\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single method (caspase assay), single lab, limited mechanistic detail in abstract\",\n      \"pmids\": [\"20189297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TWEAK-Fn14 signaling induces NF-κB-dependent upregulation of Mcl-1 in NSCLC cells, conferring Mcl-1-dependent resistance to chemotherapy and radiotherapy. Depletion of Mcl-1 (siRNA or pharmacological inhibitor EU-5148) sensitized TWEAK-treated NSCLC cells to cisplatin and radiation. Inhibition of Bcl-2/Bcl-xL had minimal effect on TWEAK-induced survival.\",\n      \"method\": \"siRNA knockdown of Mcl-1 and Fn14, pharmacological Mcl-1 inhibitor, cisplatin/radiation survival assays, NF-κB pathway analysis\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological epistasis placing Mcl-1 downstream of Fn14/NF-κB for chemo/radioresistance, single lab with multiple methods\",\n      \"pmids\": [\"24469836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TWEAK-Fn14-RelB (alternative NF-κB) signaling axis promotes cancer stem-like cell features in ovarian cancer cells after chemotherapy, including spheroid formation, asymmetric division, SOX2 expression, and EMT gene expression (VIM, ZEB1). A small-molecule Fn14 inhibitor blocking this cascade prolongs survival following carboplatin in a mouse ovarian cancer model.\",\n      \"method\": \"Fn14 small-molecule inhibitor, spheroid formation assay, asymmetric division assay, gene expression analysis, in vivo mouse ovarian cancer model\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological Fn14 blockade with multiple stem cell phenotype readouts plus in vivo survival, single lab\",\n      \"pmids\": [\"36214671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NFAT1 transcription factor increases TWEAKR (Fn14) mRNA expression in breast cancer cells. The NFAT1-LCN2 axis regulates TWEAKR expression at the RNA level. TWEAKR mediates an anti-invasive effect in breast cancer cells.\",\n      \"method\": \"NFAT1 overexpression/knockdown, LCN2 expression analysis, TWEAKR expression measurement, invasion assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, limited mechanistic detail on how NFAT1 regulates TWEAKR in abstract\",\n      \"pmids\": [\"22767506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"HGF/MET receptor activation significantly upregulates Fn14 mRNA and protein expression in NSCLC cells. Fn14 depletion is sufficient to inhibit MET-driven NSCLC tumor cell migration and invasion in vitro, placing Fn14 downstream of MET signaling for invasion.\",\n      \"method\": \"HGF treatment, Fn14 siRNA knockdown, migration/invasion assays, protein expression analysis\",\n      \"journal\": \"Clinical & experimental metastasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA epistasis placing Fn14 downstream of MET for invasion with multiple complementary assays, single lab\",\n      \"pmids\": [\"24710956\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFRSF12A (Fn14) is a highly inducible type I transmembrane receptor—the smallest TNFR superfamily member—that is activated by its cognate TNF-family ligand TWEAK; upon TWEAK binding, Fn14 recruits TRAFs to activate both canonical and non-canonical NF-κB pathways (with soluble TWEAK preferentially driving alternative NF-κB and membrane TWEAK driving both), as well as JNK, MAPK, PI3K/Akt, RhoA/MRTF-A, JAK2/STAT3, and RIPK1-dependent apoptosis cascades depending on cell context; Fn14 can also self-associate via a cytoplasmic disulfide bond at Cys122 to trigger TWEAK-independent NF-κB signaling when highly overexpressed; its expression is transcriptionally regulated by growth factors (FGF1), cytokines, mechanical stress (via RhoA/ROCK), hypoxia (via HIF-1α), androgen receptor (repressor), c-JUN (bile acid-induced), and ThPOK (repressor), while physically interacting with FGFR-1 to synergize in PI3K/Akt-driven cardiomyocyte cell cycle reentry; functionally, Fn14 is required for experience-dependent retinogeniculate synaptic refinement, myoblast fusion via Wnt/calcium signaling, burn wound healing, cardiac fibrosis via RhoA/MRTF-A/collagen, cancer cachexia (tumor cell-autonomous), and TNBC super-enhancer-driven NAMPT metabolic reprogramming for metastasis, while playing a protective anti-fibrotic role in the lung by restraining fibroblast activation and supporting pro-regenerative macrophage recruitment.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TNFRSF12A (Fn14) is the cognate receptor for the TNF-family ligand TWEAK and the smallest TNFR superfamily member, signaling through recruitment of TRAFs to drive predominantly NF-\\u03baB-based transcriptional responses in a highly cell-context-dependent manner [#0]. Ligand engagement activates canonical and non-canonical NF-\\u03baB, with soluble TWEAK and receptor dimerization preferentially triggering the alternative pathway while membrane-bound TWEAK (or oligomerized agonist antibodies) engages the full repertoire of Fn14 signaling [#6]; Fn14 can additionally self-associate via an intermolecular disulfide bond at Cys122 to activate NF-\\u03baB independently of TWEAK [#5]. Downstream, Fn14 couples to fibrogenic and inflammatory programs through RhoA-dependent MRTF-A nuclear translocation and collagen induction [#4], the TRAF3IP2 adaptor driving p38/NF-\\u03baB/AP-1 activation [#13], and JAK2/STAT3 signaling [#15], and it physically interacts with FGFR-1 to synergize in PI3K/Akt-driven cardiomyocyte cell cycle reentry [#7]. Fn14 expression is itself a highly inducible node, upregulated by mechanical stress via RhoA/ROCK [#3], growth factor and cytokine cues [#3, #31], and bile acid-driven c-JUN binding [#19], and repressed by androgen receptor [#9] and ThPOK at the promoter [#18]. Physiologically and pathologically, Fn14 mediates experience-dependent retinogeniculate synaptic refinement [#14], myoblast fusion via Wnt/calcium signaling [#22], cardiac and biliary fibrosis [#4, #21], hepatocyte cell death (RIPK1-dependent apoptosis and NF-\\u03baB/Caspase-1/GSDMD pyroptosis) [#19, #20], tumor-cell-autonomous cancer cachexia [#11], and super-enhancer-driven NAMPT metabolic reprogramming for breast cancer metastasis [#23], while conversely restraining fibroblast activation and supporting pro-regenerative macrophage recruitment in the lung [#24].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established the receptor identity of Fn14, answering what receptor transduces TWEAK signals and how it couples to downstream effectors.\",\n      \"evidence\": \"Receptor-ligand binding assays and transfection studies identifying Fn14 as the cognate TWEAK receptor signaling via TRAFs\",\n      \"pmids\": [\"12787562\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define which TRAF members are recruited or the structural basis of recruitment\", \"Did not resolve whether a second TWEAK receptor exists\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed Fn14 engagement can produce divergent outputs (NF-\\u03baB/JNK vs. weak MAPK) and that some TWEAK effects are Fn14-independent, raising the possibility of a second receptor.\",\n      \"evidence\": \"Flow cytometry, neutralizing antibodies, and signaling pathway analysis in HT-29 and RAW264.7 cells; cytotoxicity assays in Fn14-transfected cells\",\n      \"pmids\": [\"12794080\", \"12821115\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The proposed second TWEAK receptor (TweakR2) was never molecularly identified\", \"Context-dependence of NF-\\u03baB vs. MAPK output not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined Fn14 as a mechanically and humorally inducible receptor, answering how its expression is controlled upstream of TWEAK responsiveness.\",\n      \"evidence\": \"siRNA and pharmacological RhoA/ROCK inhibition in neonatal rat cardiomyocytes with NF-\\u03baB readouts\",\n      \"pmids\": [\"19629561\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not identify the transcription factors executing RhoA/ROCK-dependent Fn14 induction\", \"Restricted to cardiomyocyte context\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Resolved how Fn14 drives fibrosis by linking it to a RhoA/MRTF-A/collagen transcriptional axis and demonstrating a causal role in cardiac remodeling.\",\n      \"evidence\": \"Fn14 knockout mice with pulmonary artery banding plus in vitro fibroblast activation and MRTF-A pathway analysis\",\n      \"pmids\": [\"23325387\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define how Fn14 mechanistically activates RhoA\", \"Cross-talk with NF-\\u03baB fibrotic outputs not delineated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated TWEAK-independent signaling, answering whether Fn14 oligomerization alone is sufficient for activity and identifying Cys122 disulfide-mediated dimerization as the mechanism.\",\n      \"evidence\": \"Deletion and site-directed mutagenesis (Cys122), non-reducing SDS-PAGE, and NF-\\u03baB reporter assays\",\n      \"pmids\": [\"23750247\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of self-association at endogenous expression levels not established\", \"Did not test which signaling branches require dimerization vs. ligand\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Dissected signaling thresholds, showing dimerization triggers alternative NF-\\u03baB while higher-order clustering (membrane TWEAK or oligomerized antibody) engages all pathways.\",\n      \"evidence\": \"NF-\\u03baB reporters, IL-8 ELISA, cell death assays, and antibody oligomerization via protein G/Fc\\u03b3R cross-linking\",\n      \"pmids\": [\"23532848\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis distinguishing dimer vs. higher-order signaling not resolved\", \"TRAF-level mechanism of canonical vs. non-canonical selection not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified a direct Fn14\\u2013FGFR-1 physical interaction, answering how Fn14 can promote cardiomyocyte proliferation via PI3K/Akt cross-talk with growth factor receptors.\",\n      \"evidence\": \"Co-immunoprecipitation, proximity ligation assay, and cell cycle epistasis with PI3K/Akt analysis\",\n      \"pmids\": [\"24571920\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural interface of the Fn14\\u2013FGFR-1 complex unknown\", \"Generality beyond cardiomyocytes not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapped multiple upstream regulators and disease contexts, establishing Fn14 induction by mechanical stretch, MET, and NFAT1, repression by AR, and roles in bone metastasis and muscle disease.\",\n      \"evidence\": \"Cyclic stretch with ASK1-JNK analysis (osteoblasts), HGF/MET and NFAT1 manipulation in cancer, ChIP and IKK\\u03b2 reconstitution in bone metastasis, and knockout/anti-TWEAK rescue in a myotonic dystrophy model\",\n      \"pmids\": [\"24446436\", \"24710956\", \"22767506\", \"24970477\", \"25504044\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Context-specific reasons Fn14 is anti-invasive in some settings and pro-metastatic in others unresolved\", \"How distinct transcription factors converge on the Fn14 locus not integrated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Localized the cachexia-driving Fn14 to tumor cells rather than host tissue, answering the cell-autonomy of Fn14 in cancer-induced wasting.\",\n      \"evidence\": \"Tumor transplantation into Fn14- and TWEAK-knockout hosts plus anti-Fn14 antibody intervention with body composition analysis\",\n      \"pmids\": [\"26359988\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The tumor-derived factors downstream of Fn14 that drive wasting not fully defined\", \"Whether host TWEAK or autocrine ligand engages tumor Fn14 unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Extended Fn14 inflammatory signaling to hepatic stellate cells, showing NF-\\u03baB/STAT3 cooperation amplifies cytokine output.\",\n      \"evidence\": \"siRNA knockdown, pathway Western blotting, and Co-IP of NF-\\u03baB/STAT3 in LX-2 cells\",\n      \"pmids\": [\"28411440\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physical NF-\\u03baB/STAT3 interaction not validated reciprocally in vivo\", \"In vivo relevance to liver fibrosis not shown in this study\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified discrete downstream effectors (TRAF3IP2, JAK2/STAT3, ADAM17) and established a physiological CNS role, broadening the mechanistic and functional repertoire of Fn14.\",\n      \"evidence\": \"TRAF3IP2 knockout and siNA epistasis in cardiac fibroblasts, JAK2/STAT3 siRNA in atrial myocytes, ADAM17 siRNA in keratinocytes, and single-nucleus RNA-seq with knockout electrophysiology in dLGN neurons\",\n      \"pmids\": [\"29981796\", \"29971943\", \"28351660\", \"30033152\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the same receptor selects TRAF3IP2 vs. JAK2/STAT3 vs. ADAM17 branches per tissue is unclear\", \"Synaptic refinement effector mechanism downstream of Fn14 undefined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed Fn14 is sufficient and necessary for injury-induced pain via NF-\\u03baB activation in sensory neurons.\",\n      \"evidence\": \"Spinal nerve ligation model with Fn14 gain- and loss-of-function and p65 nuclear translocation plus behavioral testing\",\n      \"pmids\": [\"30976982\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ligand source driving neuronal Fn14 activation not identified\", \"Downstream pain-relevant NF-\\u03baB targets not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established ThPOK as a direct transcriptional repressor of TNFRSF12A, complementing earlier AR-mediated repression in defining the regulatory architecture of the locus.\",\n      \"evidence\": \"ChIP, luciferase reporter, and siRNA in gastric cancer cells with T cell co-culture\",\n      \"pmids\": [\"34353698\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interplay between activating (c-JUN, NFAT1) and repressive (ThPOK, AR) inputs at the promoter not integrated\", \"Mechanism of T cell regulation downstream of Fn14 not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Distinguished the hepatocyte cell-death mode driven by Fn14 as RIPK1-dependent apoptosis, refining how Fn14 kills cells in acute liver failure.\",\n      \"evidence\": \"TWEAK/Tnfrsf12a inhibition in TAA and APAP mouse models with pathway discrimination from necroptosis/pyroptosis and human biopsy validation\",\n      \"pmids\": [\"35853848\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Why hepatocytes use RIPK1-apoptosis vs. pyroptosis in different injuries unresolved\", \"Direct molecular link from Fn14 to RIPK1 not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Resolved a bile-acid/c-JUN-induced pyroptotic Fn14 program and a profibrogenic hepatic progenitor program, while a myoblast study placed Fn14 upstream of Wnt/calcium signaling in muscle fusion.\",\n      \"evidence\": \"Tnfrsf12a knockout cholestasis models with ChIP and Caspase-1/GSDMD analysis, Fn14 antagonism in a biliary atresia model with organoids, and conditional myoblast knockout with Wnt rescue\",\n      \"pmids\": [\"36690641\", \"36626628\", \"37813488\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Fn14 mechanistically engages the Wnt/calcium axis in myoblasts is unknown\", \"Reconciliation of Fn14 pro-death (pyroptosis) vs. pro-proliferative (HPC) hepatic roles not provided\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined a chromatin-level mechanism by which constitutive Fn14 signaling activates super-enhancers to drive NAMPT-dependent metabolic reprogramming and metastasis in TNBC.\",\n      \"evidence\": \"H3K27ac ChIP-seq, Hi-C chromatin looping, NAMPT inhibition, and in vivo xenograft metastasis with metabolic profiling\",\n      \"pmids\": [\"38965263\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The transcription factors linking Fn14/NF-\\u03baB to super-enhancer activation not fully mapped\", \"Whether this depends on TWEAK or on self-association not resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealed a protective, anti-fibrotic role for Fn14 in the lung, contrasting its profibrotic role elsewhere and identifying a specific pro-regenerative macrophage subset it supports.\",\n      \"evidence\": \"Fn14 knockout in bleomycin lung fibrosis with macrophage flow cytometry, ECM quantification, and organoid co-culture\",\n      \"pmids\": [\"39827460\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why Fn14 restrains fibroblasts in lung but activates them in heart/liver is mechanistically unexplained\", \"Signaling branch mediating chemokine-driven macrophage recruitment not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown how a single small receptor selects among its many downstream branches (canonical vs. non-canonical NF-\\u03baB, MRTF-A, TRAF3IP2, JAK2/STAT3, RIPK1-apoptosis, pyroptosis) to produce opposing tissue outcomes ranging from fibrosis promotion to fibrosis restraint.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying structural or stoichiometric model links receptor clustering state to specific downstream branch selection\", \"Determinants of pro- vs. anti-fibrotic outcomes across tissues not identified\", \"TRAF-level recruitment code not experimentally defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 6, 3]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [19, 20]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [12, 26]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [14, 22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TWEAK\", \"FGFR1\", \"TRAF3IP2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}